Krilogy Financial LLC Reduces Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Krilogy Financial LLC decreased its position in Exact Sciences Co. (NASDAQ:EXAS) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,227 shares of the medical research company’s stock after selling 3,556 shares during the period. Krilogy Financial LLC’s holdings in Exact Sciences were worth $1,193,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Chicago Partners Investment Group LLC lifted its stake in shares of Exact Sciences by 1.7% during the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock valued at $651,000 after buying an additional 158 shares during the period. Amalgamated Bank increased its position in Exact Sciences by 2.7% during the second quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock worth $462,000 after purchasing an additional 284 shares during the last quarter. Huntington National Bank increased its position in Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after purchasing an additional 352 shares during the last quarter. CIBC Asset Management Inc increased its position in Exact Sciences by 6.1% during the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after purchasing an additional 371 shares during the last quarter. Finally, Advisors Asset Management Inc. increased its position in Exact Sciences by 1.4% during the third quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock worth $1,952,000 after purchasing an additional 402 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Insider Transactions at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy acquired 19,500 shares of the stock in a transaction dated Wednesday, November 13th. The shares were bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the purchase, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on EXAS shares. Benchmark reissued a “buy” rating and issued a $65.00 price objective on shares of Exact Sciences in a research report on Monday, January 13th. Stifel Nicolaus dropped their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Monday, January 13th. Raymond James reissued a “market perform” rating on shares of Exact Sciences in a research report on Thursday, September 26th. Finally, Robert W. Baird dropped their price objective on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $72.94.

Exact Sciences Trading Up 2.6 %

Shares of NASDAQ:EXAS opened at $51.74 on Monday. The company has a market cap of $9.58 billion, a PE ratio of -44.22 and a beta of 1.24. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The company’s 50-day moving average price is $57.15 and its 200 day moving average price is $59.26. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. Exact Sciences’s revenue for the quarter was up 12.8% on a year-over-year basis. Sell-side analysts anticipate that Exact Sciences Co. will post -1.1 earnings per share for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.